Detomax200 mcg/2 ml

Detomax is a selective alpha-2 adrenergic agonist indicated for sedation in critical care and procedural settings. It must be administered only by clinicians experienced in the care of patients in an intensive care or anesthesia/procedural setting, with continuous hemodynamic monitoring.

Established (FDA-approved) uses

• Intensive care unit (ICU) sedation: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting.
• Procedural sedation: Sedation of non-intubated adult patients prior to and/or during surgical or other procedures.

Adjunct / off-label uses (regional and clinical practice)

• As an adjunct to general anesthesia to reduce the requirement for other anesthetic or opioid agents.
• In some markets, an intranasal (nasal spray) formulation of Detomax is used off-label for procedural sedation in children; this use has not been approved by the FDA and is guided by local pediatric anesthesia protocols.
• Off-label use as an adjunct in management of alcohol or opioid withdrawal symptoms and postoperative shivering in some ICU protocols.

Detomax does not reliably produce amnesia at typical sedative doses; additional analgesic or amnestic agents may be required depending on the clinical procedure.

Each mL of the sterile injectable solution contains Dexmedetomidine Hydrochloride equivalent to 100 mcg of active drug, supplied as a clear, colorless, isotonic concentrate for dilution and intravenous infusion. Available strengths and dilution requirements should be confirmed against the specific manufacturer's product label before use.

Detomax is a highly selective alpha-2 adrenergic receptor agonist, structurally related to clonidine, formulated as a sterile solution for intravenous infusion. It produces dose-dependent sedation, anxiolysis, and mild analgesia while generally preserving the ability to arouse patients to verbal stimulation, with comparatively less respiratory depression than agents acting through other receptor systems. Detomax is used exclusively in monitored clinical environments such as the intensive care unit (ICU), operating room, or procedure suite.

Alpha-2 Adrenergic Agonist; used therapeutically as a sedative-analgesic agent in critical care and procedural anesthesia settings. Detomax belongs to this pharmacologic class.

Mechanism: Dexmedetomidine Hydrochloride is a selective agonist at alpha-2 adrenergic receptors, with receptor selectivity considerably greater than clonidine. Activation of alpha-2A receptors in the locus coeruleus of the brainstem inhibits norepinephrine release, producing sedative and anxiolytic effects that resemble natural sleep, while activation of alpha-2 receptors in the spinal cord contributes to analgesic effects.

Pharmacokinetics

• Distribution: Rapidly distributed after intravenous administration; approximately 94% protein bound.
• Metabolism: Almost completely metabolized in the liver via glucuronidation and cytochrome P450-mediated (CYP2A6) oxidative pathways.
• Elimination: Metabolites are eliminated mainly via the kidneys, with a small fraction eliminated in feces; the elimination half-life is approximately 2 to 3 hours.

Detomax concentrate must be diluted with 0.9% sodium chloride injection to the required concentration before use and administered only by continuous intravenous infusion using a calibrated infusion device, never as an undiluted IV push or bolus. Administration must take place only in an ICU, operating room, or procedural setting equipped for continuous monitoring of heart rate, blood pressure, and oxygen saturation, and by personnel trained in the management of patients under general anesthesia or ICU-level sedation. Detomax is not indicated for outpatient or self-administered use.

Concomitant use of Detomax with anesthetics, sedatives, hypnotics, or opioids can produce additive central nervous system and cardiorespiratory depressant effects; a dose reduction of Detomax or the concomitant agent may be required. Co-administration with agents known to cause bradycardia or hypotension (e.g. beta-blockers, calcium channel blockers, other antihypertensives) may potentiate these effects and requires close hemodynamic monitoring. No clinically significant pharmacokinetic drug interactions mediated through major cytochrome P450 enzymes have been consistently established, but caution is warranted with any centrally acting or cardiovascular-depressant medication used concurrently with Detomax.

The most common adverse effects associated with Detomax are hypotension, bradycardia, and dry mouth, which are dose-dependent and expected pharmacologic effects. Other reported adverse effects include:

• Nausea and vomiting
• Transient hypertension, particularly during or shortly after a loading dose bolus
• Atrial fibrillation or other arrhythmias
• Hyperthermia
• Respiratory depression (less pronounced than with opioids or benzodiazepines, but can occur, particularly with concomitant sedative use)

See Precautions and Warnings for hemodynamic effects requiring monitoring.

There are limited controlled data on the use of Detomax in human pregnancy. Detomax should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision, given that it is used exclusively in acute monitored clinical settings. It is not known whether Detomax is excreted in human breast milk; a decision on breastfeeding after exposure should be made by the treating physician, weighing the clinical need against potential infant exposure.

Detomax must be administered only in a monitored clinical setting (ICU, procedural, or perioperative area) with continuous monitoring of heart rate, blood pressure, and respiratory status; it is not an outpatient or self-administered medication.

• Hypotension and bradycardia: These are common, dose-dependent, expected pharmacologic effects of Detomax. Use with caution in patients with pre-existing bradycardia, advanced heart block, severe ventricular dysfunction, or hypovolemia. A loading dose bolus, if used, can cause more pronounced transient hypertension followed by hypotension or bradycardia.
• Incomplete amnesia: Detomax does not reliably produce amnesia at typical sedative doses; additional analgesic or amnestic agents may be needed depending on the clinical context.
• Withdrawal on abrupt discontinuation: Rebound hypertension and agitation can occur with abrupt discontinuation of Detomax after a prolonged infusion; the infusion should be tapered per clinical protocol if used for an extended duration.
• Hepatic impairment: Detomax is extensively metabolized by the liver; dose adjustment may be required (see Dosage and Administration).
• Trained personnel required: Administration and monitoring of Detomax must be performed by clinicians experienced in critical care, anesthesia, or procedural sedation.

Overdose or excessive dosing with Detomax may result in pronounced bradycardia, hypotension, heart block, sedation, and respiratory depression. There is no specific antidote. Management is supportive: the infusion should be reduced or discontinued immediately, and the patient should receive supportive cardiorespiratory care, which may include intravenous fluids, positioning, vasopressors, or atropine for symptomatic bradycardia, as directed by a physician. Any suspected overdose should prompt immediate medical attention; contact emergency services or a poison control center without delay.

Store at room temperature, below 30°C, protected from light. Do not freeze. Keep out of reach of children. Use only in a monitored clinical facility; discard any diluted solution not used within the manufacturer's recommended time frame.

Hepatic impairment: Dose reduction should be considered, as Detomax is extensively hepatically metabolized (see Dosage and Administration).

Renal impairment: No specific dosage adjustment is required based on renal function, though monitoring is advised.

Elderly patients: May be more sensitive to the hemodynamic effects of Detomax; use with caution and close monitoring.

Pediatric patients: Safety and efficacy of Detomax for ICU or procedural sedation have not been formally established in children; an intranasal formulation is used off-label for procedural sedation in some markets (see Pediatric Uses).

Pregnancy and lactation: See Pregnancy and Lactation.

For ICU sedation, Detomax is typically continued for the duration that mechanical ventilation and sedation are clinically required, commonly up to 24 hours, though longer infusions are used under close monitoring in some clinical protocols. For procedural sedation, Detomax is administered only for the duration of the surgical or diagnostic procedure and the immediate recovery period. Infusions used for an extended duration should be tapered gradually rather than stopped abruptly, to reduce the risk of withdrawal-type symptoms (see Precautions and Warnings).

Alpha-2 Adrenergic Agonists; Sedative Agents (a non-benzodiazepine, non-opioid class used in critical care and anesthesia). Dexmedetomidine Hydrochloride is the representative agent of this class used in ICU and procedural sedation.

Dexmedetomidine Hydrochloride binds selectively to alpha-2 adrenergic receptors in the central nervous system. Stimulation of alpha-2A receptors in the locus coeruleus suppresses norepinephrine release and neuronal firing, producing a sedative state that resembles natural non-REM sleep with preserved arousability, rather than classical GABAergic sedation. Activation of alpha-2 receptors in the dorsal horn of the spinal cord contributes analgesic effects, and stimulation of peripheral and central alpha-2 receptors contributes to the characteristic dose-dependent hemodynamic effects (initial transient hypertension with a loading dose, followed by hypotension and bradycardia).

C

The safety and efficacy of Detomax for sedation in the intensive care unit or for procedural sedation have not been formally established in pediatric patients under standard regulatory labeling. In some countries, an intranasal (nasal spray) formulation of Detomax is used off-label for procedural sedation in children under specialist pediatric anesthesia or sedation protocols, with dosing individualized by a pediatric specialist. Use of Detomax in children should occur only under the direct supervision of a clinician experienced in pediatric sedation, with continuous cardiorespiratory monitoring.